Latest Pharma and Biotech News
Pharmaceutical
3 June 2025 The UK risks losing £11 billion ($14 billion) in pharmaceutical R&D investment by 2033 unless urgent reforms are made to high and unpredictable clawback payments imposed on medicine sales to the National Health Service, according to a new report commissioned by the Association of the British Pharmaceutical Industry (ABPI).
Today's issue
Refine Search
Pharmaceutical
Italian drug discovery specialist Axxam and German AI firm Molecular Health have struck a strategic alliance aimed at improving the precision and speed of therapeutic target identification across multiple disease areas. 4 June 2025
Biotechnology
US clinical-stage biotech Vigil Neuroscience today announced a disappointing update on the Phase II IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). 4 June 2025
Pharmaceutical
Neuropsychiatric disorders specialist Alto Neuroscience, has entered into an asset purchase agreement with Chase Therapeutics Corporation to buy a portfolio of potentially best-in-class dopamine agonist drug combinations. 4 June 2025
Pharmaceutical
Danish dermatology specialist LEO Pharma has appointed Helle Hedegaard Juhl as executive vice president for global people and corporate affairs (GPCA). 4 June 2025
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published the UK’s first official guidance to support the safe development and use of phage therapies - treatments that use viruses to target and destroy harmful bacteria. 4 June 2025
Biotechnology
US clinical-stage biotech Sagimet Biosciences today reported denifanstat met all primary and secondary endpoints in a Phase III clinical trial for the treatment of moderate to severe acne vulgaris conducted by Sagimet’s license partner Ascletis Bioscience in China. 4 June 2025
Pharmaceutical
The European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to include a new, room-temperature stable tablet for people living with spinal muscular atrophy (SMA), Swiss pharma giant Roche revealed today 4 June 2025
Pharmaceutical
The American medicines regulator has committed to reviewing the safety of the abortion pill mifepristone, amid renewed political scrutiny and pressure from conservative lawmakers. 4 June 2025
Pharmaceutical
US biotech BioAge Labs is expanding its obesity pipeline just months after shelving its lead drug in the category due to liver toxicity. 4 June 2025
Biotechnology
India’s Zydus Lifesciences announced that it has entered into a definitive agreement with Agenus to acquire India and Sri Lanka commercial rights for its investigational botensilimab (BOT) and balstilimab (BAL), combination therapy. 4 June 2025
Biotechnology
The European Commission (EC) has approved Adcetris (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. 4 June 2025
Pharmaceutical
Sogroya (somapacitan injection) has been recommended by UK health technology assessor the National Institute for Health and Care Excellence (NICE) as a treatment for people aged 3 to 17 years with pediatric growth hormone deficiency, the UK subsidiary of Denmark’s Novo Nordisk revealed yesterday. 4 June 2025
Pharmaceutical
Sweden’s Karolinska Development today revealed that its portfolio company OssDsign has carried out a directed share issue through an accelerated book-building procedure that brought the company approximately 158 million kronor ($16.5 million). 4 June 2025
Pharmaceutical
US pharma major Eli Lilly has struck a deal worth up to $870 million with Swedish biotech Camurus, securing global rights to apply the latter’s extended-release delivery platform to a set of its own metabolic disease compounds. 4 June 2025
Pharmaceutical
The American medicines regulator has approved Bayer’s Nubeqa (darolutamide) for broader use in patients with metastatic castration-sensitive prostate cancer (mCSPC), marking a step forward for the drugmakeFood and Drug Administraton,r’s prostate cancer franchise. 4 June 2025
Pharmaceutical
The UK risks losing £11 billion ($14 billion) in pharmaceutical R&D investment by 2033 unless urgent reforms are made to high and unpredictable clawback payments imposed on medicine sales to the National Health Service, according to a new report commissioned by the Association of the British Pharmaceutical Industry (ABPI). 3 June 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved SFL Pharmaceuticals Deutschland’s Aumseqa (aumolertinib) for adults with non-small cell lung cancer (NSCLC). 3 June 2025
Pharmaceutical
Shares in MaaT Pharma, a French microbiome company in oncology, closed 25% higher Tuesday. 3 June 2025
Generics
German drugmaker STADA Arzneimittel has reported record earnings on revenues growth in its financial first quarter. 3 June 2025
Pharmaceutical
Germany-based mental health specialist atai Life Sciences is to buy privately-held UK psychedelic drug developer Beckley Psytech in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase IIb success criteria. 3 June 2025
All news
Biosimilars
South Korea’s Celltrion has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), following approval by the US Food and Drug Administration (FDA) in December 2024. 13 March 2025
Pharmaceutical
Privately-held Ashvattha Therapeutics, a Californian firm advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, has announced positive Phase II data for migaldendranib, a novel subcutaneously (subQ) administered nanomedicine treatment for retinal diseases. 13 March 2025
Pharmaceutical
The European Commission (EC) has approved Danish CNS specialist Lundbeck and Otsuka Pharmaceutical Europe’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older. 13 March 2025
Pharmaceutical
Germany’s Heidelberg Pharma has modified its royalty financing agreement with HealthCare Royalty (HCRx), securing an additional $20 million upfront payment. 13 March 2025
Pharmaceutical
Insilico Medicine has raised $110 million in a series E funding round to drive the development of its artificial intelligence-powered drug candidates, including its leading drug for idiopathic pulmonary fibrosis (IPF). 13 March 2025
Pharmaceutical
US pharma giant Merck & Co has presented positive results from two pivotal Phase III trials of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF (50mg/200mg/25mg)] in trial MK-8591A-052 ) or antiretroviral therapy [baseline antiretroviral therapy (bART)] in trial MK-8591A-051. 13 March 2025
Pharmaceutical
California-based Vivace Therapeutics has announced the closing of a $35 million Series D financing. 13 March 2025
Biotechnology
France-based Oncovita, a biotech specializing in vaccine development and a spin-off from the Institut Pasteur, and Unither Pharmaceuticals, a specialist in sterile unit-dose manufacturing, have announced a strategic partnership to develop and produce a new combined prophylactic vaccine for the prevention of infectious diseases in children. 13 March 2025
Biotechnology
PranaX, a Houston, USA-based biotech specializing in exosome-based regenerative therapies, has appointed Phillip Maderia as its new chief executive as it seeks to expand its pipeline and establish a stronger foothold in the biopharmaceutical market. 12 March 2025
Biotechnology
Harbour BioMed, a global biopharmaceutical company specializing in novel antibody therapeutics for immunology and oncology, has announced the launch of Élancé Therapeutics. 12 March 2025
Biotechnology
USA-based Emergent BioSolutions and Swiss vaccines firm Rocketvax have announced an agreement. 12 March 2025
Pharmaceutical
Specialist HIV company ViiV Healthcare, which is majority owned by UK pharma major GSK, today announced positive findings from the company’s EMBRACE Phase IIb study. 12 March 2025
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical has entered into a license agreement with USA-based Ionis Pharmaceuticals for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Ionis’ shares edged up 2.4% to $33.82 on the news. 12 March 2025
Pharmaceutical
Sweden-based women’s health company Gedea Biotech has completed a clinical trial, the NEFERTITI-2 study, for the treatment of bacterial vaginosis. 12 March 2025
Pharmaceutical
Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, following the implementation of Veeva Systems' Development Cloud. 12 March 2025
Pharmaceutical
ViiV Healthcare has announced promising results from two Phase IIa studies of investigational antiretroviral therapies, VH184 and VH499. 12 March 2025
Pharmaceutical
Shares of Danish biotech Zealand Pharma were up 30% at 635.50 kroner by early afternoon, on news of a potentially lucrative licensing deal with Swiss pharm giant Roche. 12 March 2025
Pharmaceutical
US biopharma Viking Therapeutics developing therapies for metabolic and endocrine disorders, closed Tuesday’s trading 5% lower. 12 March 2025
Pharmaceutical
California commercial-stage biopharma firm Geron Corporation has announced that Dr John “Chip” Scarlett, president, chief executive (CEO) and chairman, will depart the company on March 31, 2025. 12 March 2025
Biotechnology
UK-based Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, today announces the appointment of Haseeb Ahmad as its chief executive (CEO) and member of the board of directors effective immediately. 12 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze